Department of Ophthalmology, Peking University Third Hospital, Beijing, China.
Department of Ophthalmology, Daqing Oilfield General Hospital, Heilongjiang, China.
Acta Ophthalmol. 2021 Dec;99(8):e1307-e1314. doi: 10.1111/aos.14833. Epub 2021 Apr 25.
To compare the efficacy of intense pulsed light (IPL) and near-infrared light (NIL) treatments in alleviating symptoms and signs of dry eye disease (DED).
Patients diagnosed with DED at the Peking University Third Hospital Eye Center from January 2019 to October 2019 were randomized to undergo either NIL therapy combined with meibomian gland expression (MGX; NIL Group) or IPL combined with MGX (IPL Group). Treatments were performed three times at 1-month intervals. DED signs and symptoms were evaluated before every treatment. We compared the clinical improvement within and between the groups. Additional comparisons were made according to the meibomian gland (MG) dropout grade.
A total of 260 eyes of 130 patients (mean age, 49.68 ± 18.01 years) were included. The dryness and total symptom scores and the MG expressibility and secretion quality (upper and lower eyelids) significantly improved after the three treatments in both groups (p < 0.05). However, IPL had superior efficacy in improving blurred vision, photophobia, burning, increased secretions and the total symptom score at 2 months in patients with more severe MG dropout.
Both IPL and NIL treatments were effective in the treatment of DED, but IPL provided greater symptom improvement, particularly in patients with severe MG dropout. NIL can be a new therapeutic option for the treatment of DED.
比较强脉冲光（IPL）和近红外光（NIL）治疗缓解干眼疾病（DED）症状和体征的疗效。
2019 年 1 月至 10 月，北京大学第三医院眼科中心诊断为 DED 的患者被随机分为 NIL 联合睑板腺按摩（MGX；NIL 组）或 IPL 联合 MGX（IPL 组）治疗。治疗间隔 1 个月，共 3 次。每次治疗前评估 DED 症状和体征。我们比较了组内和组间的临床改善情况。根据睑板腺（MG）缺失程度进行了额外比较。
共纳入 130 例 260 只眼（平均年龄 49.68±18.01 岁）。两组治疗后干、总症状评分及 MG 可挤出性和分泌质量（上下眼睑）均明显改善（p<0.05）。然而，对于 MG 缺失更严重的患者，IPL 在治疗 2 个月时改善视力模糊、畏光、烧灼感、分泌物增加和总症状评分方面具有更好的疗效。
IPL 和 NIL 治疗均有效治疗 DED，但 IPL 可改善更多症状，尤其是在 MG 缺失更严重的患者中。NIL 可以成为治疗 DED 的新治疗选择。
